Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

Tempus AI, Inc. (TEM)

As of 2026-11-20 · 12/15 boxes filled from SEC filings and market data

Report price $54.04 (close 2026-11-20)

Conclusion: WATCH

Conviction low · base case -48% · downside -62% · upside +19%

Despite a 39.3% drawdown from the 52-week high, the market is not missing the growth: it pays 6.26x TTM sales for a business with -$249.3M EBITDA, -$136.8M free cash flow and a -132.0% ROIC against a 19.2% WACC. The base case puts the stock at $28.16, -47.9%, on EV/Sales at 3.13x, the peer median; the downside is $20.39, -62.3%, on the base case's multiple applied to earnings 30.0% lower; the upside is $64.39, +19.2%, on 20% more sales at today's 6.26x. Data licensing, the $590.5M cash balance and the about $65M FY2026 adjusted EBITDA guide are real, but they do not yet produce GAAP profit or positive free cash flow. The call is WATCH with low conviction: this is a growth compounder read on a deep-value checklist, where the reverse DCF needing +33.0% a year for ten years is the fairer test, and the peer anchor is weak because the comps grow at different rates.

Key numbers

  • Share price: $54.04
  • Market cap: $9.86B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $1.51B
  • FCF yield: -1.4%
  • Price / book: 19.70x
  • Earnings-quality flags (TTM): Investment gains/losses $120.7M (64% of net income)
  • Revenue growth (latest fiscal year): +83.4%
  • ROIC (TTM): -132.0%
  • WACC: 19.2%
  • Economic profit spread: -151.2 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    Tempus (filed as Tempus Labs, Inc. until the December 2023 rename) sells next-generation sequencing and other diagnostic testing to providers and monetizes a de-identified copy of the resulting clinical and molecular data to life sciences customers. The latest 10-K folds the business into two product lines — Diagnostics (Oncology and Hereditary testing) and Data and applications (Insights, Next, Trials, Algos) — replacing the FY2024 three-line structure of Genomics, Data and AI Applications/Algos. Revenue grew in every year shown, from $320.7M in FY2022 to $1.27B in FY2025 and $1.51B TTM to Sep 30 2026, but operating income is still a loss (-$252.9M FY2025, -$278.9M TTM) and operating cash flow is negative (-$218.1M FY2025, -$108.4M TTM), with $590.5M of cash at Sep 30 2026. Between the oldest and newest annual report the ordering-site network widened from roughly 3,000 to more than 5,000 institutions, largely on the February 2025 Ambry Genetics acquisition that pushed the company beyond oncology.

  2. ✓ 2. Competitive advantage

    No durable advantage is visible in the numbers: Tempus has grown revenue from $320.7M in FY2022 to $1.27B in FY2025 and $1.51B TTM to Sep 2026, yet operating income was negative in every period and operating cash flow was negative in every period including -$108.4M TTM, with an accumulated deficit of $2.4 billion at 2025-12-31. The competitive set is crowded and well funded — Foundation Medicine/Roche, Caris, Guardant, Natera, Neogenomics, plus Quest and LabCorp in labs, and Flatiron, IQVIA and ConcertAI in data — and the company itself warns many rivals have substantially greater resources. Its claimed moat (network effects, proprietary technology, data) is asserted rather than demonstrated: some data-supplier arrangements are non-exclusive, and only ~55% of clinical oncology NGS tests and 50% of hereditary tests performed since 2023-01-01 had been paid as of 2025-12-31.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 revenue was $411.5 million, up 23%, and nine-month revenue was $1,142.1 million, up 26%, led by Diagnostics and Data & Applications growth. Gross profit rose 27% to $266.7 million and Adjusted EBITDA was $25.6 million, while the $(14.9) million net loss included large unrealized securities gains and stock-based compensation. Cash and marketable securities were $854.4 million, and full-year 2026 guidance is $1.60 to $1.605 billion of revenue with about $65 million of Adjusted EBITDA. The 10-Q risk-factor update says no material changes except risks tied to the proposed Personalis acquisition.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans